# Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)

> **NCT07632898** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Inhibikase Therapeutics** · enrollment: 484 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension (PAH)

## Interventions

- **DRUG:** IKT-001

## Key facts

- **NCT ID:** NCT07632898
- **Lead sponsor:** Inhibikase Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-23
- **Primary completion:** 2030-06-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 484 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07632898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07632898, "Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07632898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*